The continuing goal of the Flow Cytometry Core is to provide acquisition and analysis of any flow cytometry data needed by program investigators. For evaluation of plasma, serum, and cell culture supernatants, the core provides staining, acquisition, and analysis of expression of as many as 30 cytokines / chemokines / cytotoxic proteins / phospho-proteins per sample using the Cytometric Bead Array (CBA) multiplexing platform. The core has been providing 8-color immunophenotyping and is preparing to extend this to 10-color detection. The core stains, acquires, and analyzes the levels of expression of intracellular proteins (cytokines such as IL-6, IL-10, IL-12) and phospho-proteins (phospho-Stat3). The Aldefluor assay is employed by the core to examine expression of aldehyde dehydrogenase, which is reportedly expressed at increased levels in cancer stem cells. The core has previously demonstrated the ability of its cell sorter to perform high-purity sorting of gene-transduced cells co-expressing green fluorescent protein (GFP).
This core provides significant and essential resources to the four projects in the PPG as it allows identification of plasma/serum and supernatant analytes, cell surface immunophenotypes, quantification of intracellular proteins and phospho-proteins, reactive oxygen species (ROS), and apoptosis. The significance of work done for Projects 1-4 can be found in reports of those projects.
|Cho, Hwang Eui; Min, H Kang (2017) Analysis of fenretinide and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics. J Pharm Biomed Anal 132:117-124|
|Borriello, Lucia; Nakata, Rie; Sheard, Michael A et al. (2017) Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells. Cancer Res 77:5142-5157|
|Erdreich-Epstein, Anat; Singh, Alok R; Joshi, Shweta et al. (2017) Association of high microvessel ?v?3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126. Oncotarget 8:52193-52210|
|Tran, Hung C; Wan, Zesheng; Sheard, Michael A et al. (2017) TGF?R1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells. Clin Cancer Res 23:804-813|
|Villablanca, Judith G; Volchenboum, Samuel L; Cho, Hwangeui et al. (2016) A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma. Pediatr Blood Cancer 63:1349-56|
|Vaughan, Lynsey; Clarke, Paul A; Barker, Karen et al. (2016) Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors. Oncotarget 7:57525-57544|
|Borriello, Lucia; Seeger, Robert C; Asgharzadeh, Shahab et al. (2016) More than the genes, the tumor microenvironment in neuroblastoma. Cancer Lett 380:304-14|
|DuBois, Steven G; Marachelian, Araz; Fox, Elizabeth et al. (2016) Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. J Clin Oncol 34:1368-75|
|Trieu, Megan; DuBois, Steven G; Pon, Elizabeth et al. (2016) Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG). Pediatr Blood Cancer 63:436-42|
|Challagundla, Kishore B; Wise, Petra M; Neviani, Paolo et al. (2015) Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy. J Natl Cancer Inst 107:|
Showing the most recent 10 out of 140 publications